Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-4 Host Tissue (NECTAR) for Hospitalized COVID-19 Patients
NCT04924660Phase 3Completed
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fostamatinib, angiotensin-(1-7), TRV120027 in coronavirus disease 2019 (COVID-19). Started Jul 2021; status: completed.
02
Drugs
fostamatinibangiotensin-(1-7)TRV120027
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04924660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924660.